A tech transfer collaboration that spans Baltimore and Philly is resulting in a new startup.
Abri Science is applying materials science to a therapy treating the metabolic disorder known as PKU. The company was formed as a portfolio company of Baltimore-based startup studio Early Charm Ventures through a licensing agreement with University of the Sciences in collaboration with tech transfer and commercialization company L2C Partners, both of which are based in Philadelphia.
The company received a $225,000 Small Business Technology Transfer grant from the U.S. National Institute of Diabetes and Digestive and Kidney Diseases to further develop the technology.
READ FULL ARTICLE HERE
